Quarterly ResultNov 3, 2026, 06:12 AM
InMed Pharmaceuticals Reports Q3 Loss of $2.33M; Going Concern Doubt
AI Summary
InMed Pharmaceuticals Inc. filed its Form 10-Q for the period ended September 30, 2026, reporting a net loss of $2.33 million, an increase from $1.73 million in the same period last year. The company's cash position has significantly decreased to $1.09 million. Management has expressed substantial doubt about the company's ability to continue as a going concern. Key developments include the ongoing proposed merger with Mentari and the winding down of the BayMedica commercial business segment.
Key Highlights
- InMed Pharmaceuticals Inc. reported a net loss of $2.33 million for the three months ended September 30, 2026, compared to a net loss of $1.73 million in the prior year period.
- Research and development expenses decreased to $206,015 from $575,458 year-over-year.
- General and administrative expenses increased to $1.80 million from $1.24 million year-over-year.
- Cash and cash equivalents decreased to $1.09 million as of September 30, 2026, from $2.19 million as of June 30, 2026.
- The company has substantial doubt about its ability to continue as a going concern within one year.
- The company is pursuing a merger with Mentari, subject to shareholder approval and other conditions.
Price Impact
More from INM